Abstract
Ovarian hyperstimulation syndrome (OHSS) is a severe complication of ovarian stimulation. No reliable test exists to predict the syndrome. The objective of the present prospective observational study was to examine vascular endothelial growth factor (VEGF) secretion after human chorionic gonadotropin (hCG) administration in the luteal phase of a spontaneous cycle of women with a history of severe OHSS. Five women with a history of severe OHSS were administered 250 μg recombinant hCG intravenously on day 21 of a spontaneous menstrual cycle. Plasma samples were collected at regular intervals from 15 min before hCG to 6 h thereafter and the free VEGF plasma concentrations were determined. Plasma levels of free VEGF remained at the lower detection limit of the assay throughout the observational period. Women with previous severe OHSS do not show a significant short-time response of VEGF secretion upon hCG administration. No evidence was found to support the notion that women inclined to develop a severe form of the syndrome after ovarian stimulation could possibly be identified by the VEGF short-time secretory response to exogenous hCG in the luteal phase of a spontaneous cycle.
Similar content being viewed by others
References
Moses M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, Serr DM, David A, Salomy M (1965) Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet 2(7424):1213–1215
Ou YC, Kao YL, Lai SL, Kung FT, Huang FJ, Chang SY, ChangChien CC (2003) Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: case report. Hum Reprod 18(11):2375–2381
Elchalal U, Schenker JG (1997) The pathophysiology of ovarian hyperstimulation syndrome–views and ideas. Hum Reprod 12(6):1129–1137
McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344(8917):235–236
Lee A, Christenson LK, Stouffer RL, Burry KA, Patton PE (1997a) Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil Steril 68(2):305–311
Lee A, Christenson LK, Patton PE, Burry KA, Stouffer RL (1997b) Vascular endothelial growth factor production by human luteinized granulosa cells in vitro. Hum Reprod 12(12):2756–2761
Abramov Y, Barak V, Nisman B, Schenker JG (1997) Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 67(2):261–265
Agarwal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, Campbell S, Conway G, Jacobs H (1999) Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71(2):287–293
Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M (1995) Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 80(6):1967–1971
Robertson D, Selleck K, Suikkari AM, Hurley V, Moohan J, Healy D (1995) Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment. Hum Reprod 10(9):2478–2482
Artini PG, Monti M, Fasciani A, Tartaglia ML, D’Ambrogio G, Genazzani AR (1998) Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations in women undergoing in vitro fertilization. Gynecol Endocrinol 12(4):243–247
Agarwal R, Conway G, Sladkevicius P, Tan SL, Engmann L, Payne N, Bekir J, Campbell S, Jacobs H (1998) Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 70(4):651–658
Molskness TA, Stouffer RL, Burry KA, Gorrill MJ, Lee DM, Patton PE (2004) Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 19(4):822–830
Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK (2002) Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87(7):3300–3308
Orvieto R (2003) Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 18(4):665–667
D’Angelo A, Davies R, Salah E, Nix BA, Amso NN (2004) Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study. Fertil Steril 81(2):332–336
Ayhan A, Tuncer ZS, Aksu AT (1996) Ovarian hyperstimulation syndrome associated with spontaneous pregnancy. Hum Reprod 11(8):1600–1601
Mitchell SY, Fletcher HM, Williams E (2001) Ovarian hyperstimulation syndrome associated with clomiphene citrate. West Indian Med J 50(3):227–229
Di Carlo C, Bruno P, Cirillo D, Morgera R, Pellicano M, Nappi C (1997) Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. Hum Reprod 12(10):2115–2117
Golan A, Ron-El R, Herman A (1989) Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44:430–440
Garrido N, Albert C, Krussel JS, O’Connor JE, Remohi J, Simon C, Pellicer A (2001) Expression, production, and secretion of vascular endothelial growth factor and interleukin-6 by granulosa cells is comparable in women with and without endometriosis. Fertil Steril 76(3):568–575
Trinchard-Lugan I, Khan A, Porchet HC, Munafo A (2002) Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. Reprod Biomed Online 4(2):106–115
Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF (1998) In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275:1054–1061
Jelkmann W (2001) Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47(4):617–623
Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T (1998) The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome. J Mol Endocrinol 20(3):363–374
Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS (2000) Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 15(5):1037–1042
Enskog A, Nilsson L, Brannstrom M (2001) Plasma levels of free vascular endothelial growth factor (165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 96(2):196–201
Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo KT (1996) Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 65(3):552–555
Ludwig M, Jelkmann W, Bauer O, Diedrich K (1999) Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum Reprod 14(10):2437–2441
Licht P, Neuwinger J, Fischer O, Siebzehnrubl E, Wildt L (2002) VEGF plasma pattern in ovulation induction: evidence for an episodic secretion and lack of immediate effect of hCG. Exp Clin Endocrinol Diabetes 110(3):130–133
Nielsen HJ, Werther K, Mynster T, Brunner N (1999) Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 39(10):1078–1083
Rodriguez CR, Fei DT, Keyt B, Baly DL (1998) A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor 165 in human plasma. J Immunol Methods 219(1–2):45–55
Licht P, Neuwinger J, Fischer O, Siebzehnrubl E, Wildt L (2001) Peripheral levels of vascular endothelial growth factor (VEGF) are higher in gonadotropin stimulated as compared to natural ovarian cycles. Exp Clin Endocrinol Diabetes 109(6):345–349
Albert C, Garrido N, Mercader A, Rao CV, Remohi J, Simon C, Pellicer A (2002) The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod 8(5):409–418
Ziecik AJ, Derecka-Reszka K, Rzucidlo SJ (1992) Extragonadal gonadotropin receptors, their distribution and function. J Physiol Pharmacol 43(4 Suppl 1):33–49
Toth P (2001) Clinical data supporting the importance of vascular LH/hCG receptors of uterine blood vessels. Semin Reprod Med 19(1):55–61
Vasseur C, Rodien P, Beau I, Desroches A, Gerard C, de Poncheville L, Chaplot S, Savagner F, Croue A, Mathieu E, Lahlou N, Descamps P, Misrahi M (2003) A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 349(8):753–759
Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S (2003) Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 349(8):760–766
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Griesinger, G., Dafopoulos, K., Schultze-Mosgau, A. et al. Vascular endothelial growth factor response to exogenous chorionic gonadotropic hormone in the luteal phase of women with a history of severe ovarian hyperstimulation syndrome. Arch Gynecol Obstet 274, 29–33 (2006). https://doi.org/10.1007/s00404-005-0112-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-005-0112-0